Australian company Aravax has announced that the first patient has been dosed in its Phase 2 study (AVX-201) of investigative candidate PVX108 for the treatment of peanut allergy. …
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 1 August
August 1, 2025 - - Podcast -
Trump administration takes another step in 'Most Favored Nation' push
August 1, 2025 - - Latest News -
Novartis backs the launch of a new cardiovascular disease program
August 1, 2025 - - Latest News -
Study reveals growing benefit of Lilly therapy for early symptomatic Alzheimer’s disease
August 1, 2025 - - Latest News -
New pharmacy-focused partnership marks the launch of two first-to-market biosimilars
August 1, 2025 - - Latest News -
Arrotex expands haematology-oncology portfolio through Antengene partnership
August 1, 2025 - - Latest News -
AbbVie therapy now available on the PBS for treatment of advanced Parkinson’s
August 1, 2025 - - Latest News